Anti-EDEM1 antibody,Mouse monoclonal

Monoclonal Anti-EDEM1 (mouse IgG2a isotype) is derived from the hybridoma EDEM1-17 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to a fragment of human EDEM1. conjugated to keyhole limpet hemocyanin (KLH). EDEM1 (ER degradation-enhancing alphamannosidase-like protein 1) is a putative mannose binding lectin. In mammalian cells, EDEM1 is localized to the endoplasmic reticulum (ER), mainly as a soluble glycoprotein.

Monoclonal Anti-EDEM1 antibody produced in mouse has been used in:

• immunoblotting
• immunoprecipitation
• immuno-electron microscopy
• immunohistochemistry (IHC)

EDEM1 (ER degradation-enhancing alphamannosidase-like protein 1) has the ability to interact with the COOH-terminus of calnexin. It lacks mannosidase activity.

ER degradation-enhancing α-mannosidase-like 1 is an enzyme encoded by the EDEM1 gene in humans. It is a chaperone for rod opsin and its expression can be used to promote correct folding enhancing degradation of mutant proteins in the ER to combat protein-misfolding disease. The endogenous EDEM1 in cells that are not stressed by the expression of a transgenic misfolded protein reaches the cytosol and is degraded by basal autophagy. EDEM may maintain the retrotranslocation competence of NHK by inhibiting aggregation. It is also considered responsible for directing aberrant proteins for ERAD (ER-associated protein degradation).

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.